- Home
- OPHC vs IMA Comparison
OPHC vs IMA Comparison
Compare OPHC & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | IMA |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 66.3M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | OPHC | IMA |
|---|---|---|
| Price | $5.73 | $5.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $6.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 37.2K | 9.4K |
| Earning Date | 04-24-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17,095.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $3.94 |
| 52 Week High | $5.90 | $17.50 |
Technical Indicators
Market Signals| Indicator | OPHC | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 47.42 |
| Support Level | $5.40 | $5.70 |
| Resistance Level | $5.90 | $6.06 |
| Average True Range (ATR) | 0.15 | 0.31 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 55.26 | 39.73 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.